On June 23, 2026, Lupin Pharmaceuticals Inc. initiated a recall of its Glucagon Emergency Kit for Low Blood Sugar. The recall is classified as Class II by the FDA.
The action affects Glucagon for Injection USP, 1mg per vial, packaged with a Diluent for Glucagon and a 1 mL syringe, NDC 70748-311-01. The product is manufactured by Lupin Limited in Nagpur, India, for Lupin Pharmaceuticals, Inc. of Naples, FL.
According to the FDA record, the recall was prompted by a CGMP deviation. An out-of-specification result was observed for the Gliding Force functionality test during 12-month long term stability testing.
The recall status is listed as ongoing. The FDA classification and the manufacturer's stated reason are reported here as facts from the recall record, without additional interpretation.
Glucagon remains an approved product. For general background on this compound, readers can consult the compound overview.